The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th - 7th February 2020 in San Diego, CA would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics areas. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

What are the essentials being missed out on? What is the real role of probiotics strains, prebiotics and symbiotic in influencing a health? How do you standardize microbiome analysis?

Witness the major breakthroughs of microbiome, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery.

Regenerative therapies are proving its acceptance in potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.

In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

Around 1 in 20 (6%) of patients are affected by preventable harm in medical care, of which around 12% causes permanent disability or death, according to a study published by The BMJ. These infections are contracted by an estimated 1.7 million patients annually and responsible for 99,000 deaths each year.

Preventing disease and controlling spread of resistant bacteria is of major importance when tackling antibiotic resistance.  Already, AMR infections are estimated to cause 700,000 deaths each year globally, which is predicted to rise to 10 million, alongside a cumulative cost of $100 trillion, by 2020 if no action is taken.

Where does your success begin? With constant development emerging in global marketing scenario, things have become far more complicated then it seems. Smarter marketing solutions opted by the Chief Marketing professionals give the holistic view over the depth of any industry, economically and ideologically. These solutions help organizations improve their measurement and strategic planning. Smarter the solutions, better the outcomes.

Global investments in renewable and clean energy continue to grow all over the world with a continued upgrade in energy policies. Continued technology improvements and the influence of new financing guidelines and regulations continue to intensify the opportunities in the energy space. Now, supported by advances in emerging technologies like artificial intelligence, blockchain, the internet of things and more, the growing digitization, automation, communication, connectivity, and decentralization are on their way to fundamentally transform the way nations manage diverse energy sources, supply chains, and energy management processes.

The cytotoxic nature of HPAPIs presents significant handling challenges and thus requires heavy investments for implementing specialized containment facilities that facilitate the safety of employees from exposure. Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. 

One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations. 

MarketsandMarkets is proud to announce the 4th Annual High Potent Medicines Conference to be held on 28-29 May 2020 in Rome, Italy. This conference would address the challenges in the continual evolution of industry standards, technologies, and regulations. Leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations, live case studies and breakthrough panel discussions.

Increasing pressure faced by pharmaceutical companies to make their supply chain more efficient, cost effective, focussed and more agile has made the industry increasingly competitive in the recent years.

With the mandate for serialization, strict quality regulations and increasing importance of patient centricity for pharma companies to follow, it is essential to navigate from complex supply chain ecosystem to simpler processes.

“What makes I-O transformative?” Innovative approaches in patient selection, use of combinations, and sequencing of therapies lead to more patients benefitting from I-O therapy, expanding its potential impact and this also makes it more promising- from the basics of immunotherapies to the latest research results. The rapid development of immuno-oncology (I-O) therapies has transformed the treatment landscape and brightened the long-term outlook for many patients with advanced cancer.

Over the last decade, the field of cell therapy has rapidly grown, and it holds enormous promise for treating many diseases. In our conference of 2017, we assessed the specific risks and benefits of the cell culture and cell therapy bio-manufacturing for the cure of these diseases.

There are still factors like manufacturing maze, investment, logistics and regulatory challenges which prevents the cell and gene therapies to be widely used. We are once again putting together a unique platform to provide the exact solutions to these robust manufacturing and bioprocessing challenges, at our MarketsandMarkets 2nd Annual Cell Therapy Bioprocessing Conference, taking place at Boston-USA on 25th & 26th June 2020.

Industry 4.0 influences mission-critical applications in business processes and the manufacturing companies that take the risk and are early adopters of new technology will be rewarded for their progressive decision-making. Since, digitization helps to ensure product quality and safety, as well as faster service delivery, which goes a long way with customers. This has made the revolution as the need of hour!

The successful inaugural event of MarketsandMarkets Industry 4.0 Conference-Chicago, focused on the impact of IIOT and Cybersecurity, by addressing a series of application-based illustrations and discussions to map the future possibility of trends in the manufacturing world.

MarketsandMarkets is proud to announce the 3rd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress to be held on October 22-23, 2019 in Boston, USA.

While the 2nd annual Congress had discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation, the 3rd Annual will focus on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers.